The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Her-2/ neu and Breast Cancer
Abstract
Breast cancer is the most common malignancy in women in the United States in the year 2000. The proto-oncogene Her-2/neu (c-erb-B2) has become an increasingly important prognostic and predictive factor in breast cancer. Overexpression/amplification of the Her-2/neu has been associated with a worse outcome in patients with breast cancer. Herceptin, a "humanized" murine monoclonal antibody directed against the extracellular domain of the Her-2/neu protein, is being used to treat breast cancer that overexpresses Her-2/neu. The status of Her-2/neu in the tumor has become a critical factor in the management strategy of a breast cancer patient. The objective of this article is to provide a comprehensive review of all aspects of Her-2/neu in breast cancer, including biology, prognostic and predictive value, targeted Herceptin therapy, and the laboratory testing of Her-2/neu.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Rowinsky, E. K., & Donehower, R. C. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504133321507 · Cited by 1,924
Cited by
HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target
Gravalos, C., & Jimeno, A. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn169 · Cited by 1,184
Clinical proteomics: translating benchside promise into bedside reality
Petricoin, E. F., Zoon, K. C., Kohn, E. C., Barrett, J. C., & Liotta, L. A. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd891 · Cited by 550
Van Cutsem, E., de Haas, S., Kang, Y.-K., Ohtsu, A., Tebbutt, N. C., Ming Xu, J., Peng Yong, W., Langer, B., Delmar, P., Scherer, S. J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.9824 · Cited by 477
Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy
Meng, X., Huang, Z., Teng, F., Xing, L., & Yu, J. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.11.001 · Cited by 401
HER-2/neu Amplification Is an Independent Prognostic Factor in Gastric Cancer
Park, D. I., Yun, J. W., Park, J. H., Oh, S. J., Kim, H. J., Cho, Y. K., Sohn, C. I., Jeon, W. K., Kim, B. I., Yoo, C. H., et al. (2006) · Digestive Diseases and Sciences · doi:10.1007/s10620-005-9057-1 · Cited by 329
Metadata
- Authors
- Kaptain, S., Tan, L. K., & Chen, B.
- Venue
- Diagnostic Molecular Pathology
- Published
- 2001-09
- Volume
- 10
- Issue
- 3
- Pages
- 139-152
- ISSN
- 1052-9551 (ISSN-L)
- OpenAlex
- W2051566114
- Cited by
- 208
- References
- 2
- FWCI
- 6.65
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Her-2/ neu and Breast Cancer. https://app.cochat.ai/papers/10.1097/00019606-200109000-00001
- The paper
- Kaptain, S., Tan, L. K., & Chen, B. (2001). Her-2/ neu and Breast Cancer. Diagnostic Molecular Pathology. https://doi.org/10.1097/00019606-200109000-00001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.